Pontifícia Universidade Católica do Paraná Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2006
NCT02089867
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Jose Rocha Faria Neto | Pontifícia Universidade Católica do Paraná

Active Ingredients

Drugs in Phase 4 Trials (1)

icodextrin (Extraneal) (1 trial)

Drugs in Phase 3 Trials (3)

bone marrow derived mesenchymal stem cells (1 trial)

ezetimibe (zetia) (1 trial)

phytosterol (1 trial)

Drugs in Phase 2 Trials (1)

autologous mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Myocardial Ischemia (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5